Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The FDA has granted approval for AbbVie’s 15mg Rinvoq (upadacitinib) to treat adults with giant cell arteritis (GCA).

Shares of AbbVie Inc. rose 3.38% to $192.34 Monday, on what proved to be an all-around great trading session for the stock ...

With the potential for pharmaceutical import tariffs spurring a rush of life sciences investments in the U.S., AbbVie is ...

AbbVie is a popular stock with dividend investors for its high starting yield and continuous dividend increases. AbbVie is a ...

AbbVie generated $56 billion in revenue, achieving an operating profit of $12 billion and a net income of $4.3 billion, ...

AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV ...

AbbVie (NYSE:ABBV), a biopharmaceutical company, is engaged in the research and development, manufacture, commercialization, ...

All U.S. service members aboard the USS Harry S. Truman have been accounted for and are safe after a fighter jet, an F/A-18E ...

Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other capabilities over the next decade, ...

AbbVie has become the latest pharma group to make a big capital investment announcement in the US and court favour with the ...

The analyst continues to be positive on AbbVie, as he maintained his outperform (buy, in other words) recommendation on the stock and $215 per-share price target. Not surprisingly, according to ...